Department of Population and Public Health Sciences, Keck School of Medicine of University of Southern California, University of Southern California, CA, USA.
Norris Comprehensive Cancer Center, Keck School of Medicine of University of Southern California, University of Southern California, CA, USA.
JBI Evid Synth. 2024 Jul 1;22(7):1347-1354. doi: 10.11124/JBIES-23-00296.
This scoping review will identify the patterns of survival, treatment, and recurrence among Hispanic and/or Latino/a/x (H/L) patients with colorectal cancer (CRC) living in the United States (US) and Puerto Rico. Additionally, population- and individual-level determinants of cancer outcomes among H/L CRC patients will be mapped to highlight under-reported/under-investigated research areas.
CRC is the third most common cancer excluding skin cancers in the US. Unlike non-Hispanic White populations, cancer is the number one cause of death in H/L populations and currently represents 21% of total deaths. Despite this, a lack of consensus exists on CRC outcomes for H/L patients. Most research on H/L individuals has examined incidence and screening of CRC, with fewer studies focusing on cancer outcomes.
All epidemiological study designs and systematic reviews will be considered. The review will only include peer-reviewed studies that report on survival, treatment, and/or recurrence patterns for H/L patients with CRC residing in the US and Puerto Rico.
A 3-step search with a 2-stage study selection process will be followed, as recommended by JBI and Arksey and O'Malley. Databases to be searched will include MEDLINE (PubMed), Embase (Ovid), and Scopus. A data extraction tool will be designed based on JBI recommendations. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRSIMA-ScR) will be used, with the results presented in a PRISMA diagram. Publications in English from database inception to the present will be considered.
Open Science Framework https://osf.io/y6qf5.
本范围综述旨在确定居住在美国(美国)和波多黎各的西班牙裔和/或拉丁裔(H/L)结直肠癌(CRC)患者的生存、治疗和复发模式。此外,还将绘制 H/L CRC 患者癌症结局的人群和个体水平决定因素图,以突出报告/研究不足的研究领域。
CRC 是美国除皮肤癌外第三大常见癌症。与非西班牙裔白人人群不同,癌症是 H/L 人群的第一大死因,目前占总死亡人数的 21%。尽管如此,对于 H/L 患者的 CRC 结局仍缺乏共识。大多数关于 H/L 个体的研究都集中在 CRC 的发病率和筛查上,而很少有研究关注癌症结局。
所有流行病学研究设计和系统评价都将被考虑。本综述仅包括报告居住在美国和波多黎各的 H/L 结直肠癌患者生存、治疗和/或复发模式的同行评议研究。
将遵循 JBI 和 Arksey 和 O'Malley 推荐的 3 步搜索和 2 阶段研究选择过程。将搜索的数据库包括 MEDLINE(PubMed)、Embase(Ovid)和 Scopus。将根据 JBI 建议设计数据提取工具。将使用扩展后的系统评价和荟萃分析的首选报告项目(PRSIMA-ScR),结果将以 PRISMA 图呈现。将考虑从数据库开始到现在发表的英文出版物。
开放科学框架 https://osf.io/y6qf5。